Expression patterns of CD200 and CD148 in leukemic B-cell chronic lymphoproliferative disorders and their potential value in differential diagnosis
Expression patterns of CD200 and CD148 in leukemic B-cell chronic lymphoproliferative disorders and their potential value in differential diagnosis
复制标题
DOI：
10.3109/10428194.2015.1030642
复制
发表时间：
2015-12-02
影响因子：
2.6
通讯作者：
Li, Jian-Yong
中科院分区：
文献类型：
--
作者：
Fan, Lei;Miao, Yi;Li, Jian-Yong
流式细胞术分析不同的生物标志物组合对白血病B细胞慢性淋巴增生性疾病(B-CLPD)的准确诊断至关重要。应用多色流式细胞术检测了374例B-CLPD患者外周血或骨髓中CD200和CD148的表达。结果表明，CD200和CD148的表达模式可区分不同类型的B-CLPD。CD200平均荧光强度(MFI)或CD148MFI对套细胞淋巴瘤(MCL)和慢性淋巴细胞白血病(CLL)的鉴别诊断具有较高的敏感性和特异性。CD148MFI/CD200MFI比值为4.79的特异性为94.46%(95%可信区间为91.04-96.87%)，敏感性为100%(95%可信区间为88.78-100.0%)。因此，CD200和CD148联合检测对白血病B-CLPD，尤其是CLL和MCL有潜在的鉴别诊断价值。
Different combinations of biomarkers analyzed by flow cytometry are critical for the accurate diagnosis of leukemic B-cell chronic lymphoproliferative disorders (B-CLPDs). We investigated CD200 and CD148 expression patterns of blood or bone marrow from 374 cases of B-CLPD by multicolor flow cytometry. Our results showed that CD200 and CD148 expression patterns distinguished different types of B-CLPD. CD200 mean fluorescence intensity (MFI) or CD148 MFI had a high sensitivity and specificity to differentiate mantle cell lymphoma (MCL) from chronic lymphocytic leukemia (CLL). Furthermore, CD148 MFI/CD200 MFI ratio >4.79 produced a specificity of 94.46% (95% confidence interval [CI]: 91.04-96.87%) and a sensitivity of 100% (95% CI: 88.78-100.0%) in establishing the diagnosis of MCL in differential diagnosis between MCL and CLL. We therefore conclude that the combination of CD200 and CD148 may have a potential differential diagnostic value in leukemic B-CLPDs, especially between CLL and MCL.